

**DAFTAR PUSTAKA**

- Abdallah M, Badawi M, Amirah MF, Rasheed A, Mady AF, Alodat M et al (2017) Impact of carbapenem restriction on the antimicrobial susceptibility pattern of *Pseudomonas aeruginosa* isolates in the ICU. *J Antimicrob Chemother* 72(11):3187–3190
- Bradley, J. S., et al. 1999. Carbapenems in clinical practice: a guide to their use in serious infection. *Int. J. Antimicrob. Agents* 11:93–100.
- Bitterman R, Hussein K, Leibovici L, Carmeli Y, Paul M (2016) Systematic review of antibiotic consumption in acute care hospitals. *Clin Microbiol Infect* 22(6):561
- CDC (2011) ‘Gram-Negative Bacteria in Healthcare Setting’. Available at: <https://www.cdc.gov/hai/organisms/gram-negative-bacteria.html%0A>.
- CDC (2013) ‘Antibiotic resistance threats in the United States, 2013’, Current, p.114. doi: CS239559-B.
- Cunha, A, Burke., 2014, Antibiotic Essentials, 7th ed, Sudbury,MA,Jones and Bartlett Publishers,pp.1-20
- Chouchani, C., R. Marrakchi, and A. El Salabi. 2011. Evolution of lactamsresistance in Gram-negative bacteria in Tunisia. *Crit. Rev. Microbiol.*37:167–177.
- Davey, P., Irving, W., Thwaites, G., Wilcox, M. (2015) *Antimicrobial Chemotherapy*. 7th edn. Oxford University Press Inc.
- Detsis M, Karanika S, Mylonakis E (2017) ICU acquisition rate, risk factors, and clinical significance of digestive tract colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and metaanalysis. *Crit Care Med* 45(4):705–714
- Eisenstein, B. and Schaechter, M. (2013) ‘Establishment of Infectious Disease’, in Engleberg, N., DiRita, V., and Dermody (eds) *Schaechter’s Mechanisms of Microbial Disease*. Philadelphia: Lippincott Williams & Wilkins, pp. 1–10.
- Fernandez-Cuenca, F., L. Martinez-Martinez, A. Pascual, and E. J. Perea. 2003. In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of *Acinetobacter baumannii*. *Chemotherapy* 49:24–26.

- Galleni, M., G. Amicosante, and J. M. Frere. 1988. A survey of the kinetic parameters of class C  $\beta$ -lactamases. Cephalosporins and other  $\beta$ -lactam compounds. *Biochem. J.* 255:123–129.
- Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A et al (2016) Understanding the mechanisms and drivers of antimicrobial resistance. *Lancet* 387(10014):176–187
- Huang, H., and R. E. Hancock. 1996. The role of specific surface loop regions in determining the function of the imipenem-specific pore protein OprD of *Pseudomonas aeruginosa*. *J. Bacteriol.* 178:3085–3090.
- Jean, S. S., Lee, W. S., Lam, C., Hsu, C. W., Chen, R. J., and Hsueh, P. R. (2015). Carbapenemase-producing gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. *Future Microbiol.* 10, 407–410
- Logan, L. K., and Weinstein, R. A. (2017). The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. *J. Infect. Dis.* 215, S28–S36. doi: 10.1093/infdis/jiw282
- Mazzeffi M, Gammie J, Taylor B, Cardillo S, Haldane-Lutterodt N, Amoroso A et al (2017) Healthcare-associated infections in cardiac surgery patients with prolonged intensive care unit stay. *Ann Thorac Surg* 103(4):1165–1170
- Misra, R., and V. N. Bavro. 2009. Assembly and transport mechanism of tripartite drug efflux systems. *Biochim. Biophys. Acta* 1794:817–825.
- Pearson, J. P., C. Van Delden, and B. H. Iglewski. 1999. Active efflux and diffusion are involved in transport of *Pseudomonas aeruginosa* cell-to-cell signals. *J. Bacteriol.* 181:1203–1210.
- Radji Maksum.,(2014). Mekanisme aksi molekuler.Antibiotik dan kemoterapi.EGC.Jakarta. hal. 2-10
- Raman G, Avendano EE, Chan J, Merchant S, Puzniak L (2018) Risk factors for hospitalized patients with resistant or multidrug-resistant *Pseudomonas aeruginosa* infections: a systematic review and meta-analysis. *Antimicrob Resist Infect Control* 7:79
- Ruppé E, Woerther PL, Barbier F (2015) Mechanisms of antimicrobial resistance in Gram-negative bacilli. *Ann Intensive Care* 5:21
- Rodriguez-Martinez, J. M., L. Poirel, and P. Nordmann. 2009. Molecular epidemiology and mechanisms of carbapenem resistance in

- Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 53:4783–4788.
- Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S, Markaki V, Vrettou C, Paniara O, Giamarellou H, Roussos C (2010) Carbapenem-resistant versus carbapenem-susceptible *Acinetobacter baumannii* bacteremia in Greek intensive care unit: risk factors, clinical features and outcomes. *Infection* 38:173–180
- Rolinson, G. N. 1991. Evolution of  $\beta$ -lactamase inhibitors. *Rev. Infect. Dis.* 13(Suppl. 9):S727–S732.
- Riera, E., et al. 8 June 2011. *Pseudomonas aeruginosa* carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. *J. Antimicrob. Chemother.* doi:10.1093/jac/dkr232
- Tam, V. H., A. N. Schilling, R. E. Lewis, D. A. Melnick, and A. N. Boucher. 2004. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. *Antimicrob. Agents Chemother.* 48:4315–4321.
- Tsai, H. T., J. T. Wang, C. J. Chen, and S. C. Chang. 2008. Association between antibiotic usage and subsequent colonization or infection of extensive drug-resistant *Acinetobacter baumannii*: a matched case-control study in intensive care units. *Diagn. Microbiol. Infect. Dis.* 62:298–305.
- Timsit, Francois-Jean, et al. 2019. Rationalizing antimicrobial therapy in the ICU : a narrative review, Springer Verlag, GmbH Germany, *Intensive Care Med* <https://doi.org/10.1007/s00134-019-05520-5>
- Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M et al (2018) Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. *Lancet Glob Health* 6(6):e619–e629
- Walsh, T. R. 2010. Emerging carbapenemases: a global perspective. *Int. J. Antimicrob. Agents* 36(Suppl. 3):S8–S14.
- WHO (2014) ‘Antimicrobial resistance. Global Report on Surveillance’, *Bulletin of the World Health Organization*, 61(3), pp. 383–94. doi: 10.1007/s13312014- 0374-3.